Verdinexor - Antengene Therapeutics/Karyopharm Therapeutics
Alternative Names: ATG-527; KPT-335Latest Information Update: 28 Jun 2024
At a glance
- Originator Karyopharm Therapeutics
- Developer Antengene Corporation; Karyopharm Therapeutics
- Class Antineoplastics; Antivirals; Hydrazines; Pyridines; Small molecules; Triazoles
- Mechanism of Action Exportin 1 protein inhibitors; Nuclear export inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteosarcoma
- No development reported Post-transplant lymphoproliferative disorder; Systemic lupus erythematosus; Viral infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in EBV-associated B-cell hyperplasia in renal transplant recipients in Unknown (PO)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Unknown (PO)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Australia (PO)